This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Friedberg, J. W. Articles by Freedman, A. S. Search for Related Content PubMed PubMed Citation Articles by Friedberg, J. W. Articles by Freedman, A. S.

Outcome in Patients With Myelodysplastic Syndrome After Autologous Bone Marrow Transplantation for Non-Hodgkin's Lymphoma

From the Divisions of Adult Oncology and Biostatistics, Dana-Farber Cancer Institute; Departments of Medicine and Radiation Therapy, Brigham and Women's Hospital; and Departments of Medicine and Radiation Oncology, Harvard Medical School, Boston, MA.

Address reprint requests to Arnold S. Freedman, MD, Division of Adult Oncology, Dana-Farber Cancer Institute, 44 Binney St, Boston, MA 02115; email arnold_freedman{at}dfci.harvard.edu

PURPOSE: The absolute risk of myelodysplastic syndrome (MDS) after autologous bone marrow transplant (ABMT) for non–Hodgkin's lymphoma (NHL) exceeds 5% in several reported series. We report the outcome of a large cohort of patients who developed MDS after ABMT for NHL.

PATIENTS AND METHODS: Between December 1982 and December 1997, 552 patients underwent ABMT for NHL, with a uniform ablative regimen of cyclophosphamide and total body irradiation followed by reinfusion of obtained marrow purged with monoclonal antibodies. MDS was strictly defined, using the French-American-British classification system, as requiring bone marrow dysplasia in at least two cell lines, with associated unexplained persistent cytopenias.

RESULTS: Forty-one patients developed MDS at a median of 47 months after ABMT. The incidence of MDS was 7.4%, and actuarial incidence at 10 years is 19.8%, without evidence of a plateau. Patients who developed MDS received significantly fewer numbers of cells reinfused per kilogram at ABMT (P = .0003). Karyotypes were performed on bone marrow samples of 33 patients, and 29 patients had either del(7) or complex abnormalities. The median survival from diagnosis of MDS was 9.4 months. The International Prognostic Scoring System for MDS failed to predict outcome in these patients. Thirteen patients underwent allogeneic BMT as treatment for MDS, and all have died of BMT-related complications (11 patients) or relapse (two patients), with a median survival of only 1.8 months.

CONCLUSION: Long-term follow-up demonstrates a high incidence of MDS after ABMT for NHL. The prognosis for these patients is uniformly poor, and novel treatment strategies are needed for this fatal disorder.

This article has been cited by other articles:

				J. W. Friedberg Secondary malignancies after therapy of indolent non-Hodgkin's lymphoma Haematologica, March 1, 2008; 93(3): 336 - 338. [Full Text] [PDF]

				J. W. Friedberg, P. Cohen, L. Chen, K. S. Robinson, A. Forero-Torres, A. S. La Casce, L. E. Fayad, A. Bessudo, E. S. Camacho, M. E. Williams, et al. Bendamustine in Patients With Rituximab-Refractory Indolent and Transformed Non-Hodgkin's Lymphoma: Results From a Phase II Multicenter, Single-Agent Study J. Clin. Oncol., January 10, 2008; 26(2): 204 - 210. [Abstract] [Full Text] [PDF]

				A. Z.S. Rohatiner, L. Nadler, A. J. Davies, J. Apostolidis, D. Neuberg, J. Matthews, J. G. Gribben, P. M. Mauch, T. A. Lister, and A. S. Freedman Myeloablative Therapy With Autologous Bone Marrow Transplantation for Follicular Lymphoma at the Time of Second or Subsequent Remission: Long-Term Follow-Up J. Clin. Oncol., June 20, 2007; 25(18): 2554 - 2559. [Abstract] [Full Text] [PDF]

				L. Farina and P. Corradini Current role of allogeneic stem cell transplantation in follicular lymphoma Haematologica, May 1, 2007; 92(5): 580 - 582. [Full Text] [PDF]

				J. G. Gribben, D. Zahrieh, K. Stephans, L. Bartlett-Pandite, E. P. Alyea, D. C. Fisher, A. S. Freedman, P. Mauch, R. Schlossman, L. V. Sequist, et al. Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia Blood, December 15, 2005; 106(13): 4389 - 4396. [Abstract] [Full Text] [PDF]

				J. R. Brown and A. S. Freedman In Reply: J. Clin. Oncol., November 1, 2005; 23(31): 8121 - 8122. [Full Text] [PDF]

				R. Bhatia, K. Van Heijzen, A. Palmer, A. Komiya, M. L. Slovak, K. L. Chang, H. Fung, A. Krishnan, A. Molina, A. Nademanee, et al. Longitudinal Assessment of Hematopoietic Abnormalities After Autologous Hematopoietic Cell Transplantation for Lymphoma J. Clin. Oncol., September 20, 2005; 23(27): 6699 - 6711. [Abstract] [Full Text] [PDF]

				J. R. Brown, H. Yeckes, J. W. Friedberg, D. Neuberg, H. Kim, L. M. Nadler, and A. S. Freedman Increasing Incidence of Late Second Malignancies After Conditioning With Cyclophosphamide and Total-Body Irradiation and Autologous Bone Marrow Transplantation for Non-Hodgkin's Lymphoma J. Clin. Oncol., April 1, 2005; 23(10): 2208 - 2214. [Abstract] [Full Text] [PDF]

				A. T. Look Molecular Pathogenesis of MDS Hematology, January 1, 2005; 2005(1): 156 - 160. [Abstract] [Full Text] [PDF]

				J. W. Friedberg Radioimmunotherapy for Non-Hodgkin's Lymphoma Clin. Cancer Res., December 1, 2004; 10(23): 7789 - 7791. [Full Text] [PDF]

				S. Montoto, A. Lopez-Guillermo, A. Altes, G. Perea, A. Ferrer, M. Camos, L. Villela, F. Bosch, J. Esteve, F. Cervantes, et al. Predictive value of Follicular Lymphoma International Prognostic Index (FLIPI) in patients with follicular lymphoma at first progression Ann. Onc., October 1, 2004; 15(10): 1484 - 1489. [Abstract] [Full Text] [PDF]

				J. Czyz, R. Dziadziuszko, W. Knopinska-Postuszuy, A. Hellmann, L. Kachel, J. Holowiecki, J. Gozdzik, J. Hansz, A. Avigdor, A. Nagler, et al. Outcome and prognostic factors in advanced Hodgkin's disease treated with high-dose chemotherapy and autologous stem cell transplantation: a study of 341 patients Ann. Onc., August 1, 2004; 15(8): 1222 - 1230. [Abstract] [Full Text] [PDF]

				S. Smeland, A. K. Blystad, S. O. Kvaloy, I. M. Ikonomou, J. Delabie, G. Kvalheim, J. Hammerstrom, G. F. Lauritzsen, and H. Holte Treatment of Burkitt's/Burkitt-like lymphoma in adolescents and adults: a 20-year experience from the Norwegian Radium Hospital with the use of three successive regimens Ann. Onc., July 1, 2004; 15(7): 1072 - 1078. [Abstract] [Full Text] [PDF]

				K. van Besien, F. R. Loberiza Jr, R. Bajorunaite, J. O. Armitage, A. Bashey, L. J. Burns, C. O. Freytes, J. Gibson, M. M. Horowitz, D. J. Inwards, et al. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma Blood, November 15, 2003; 102(10): 3521 - 3529. [Abstract] [Full Text] [PDF]

				T. A. Lister High-Dose Therapy for Follicular Lymphoma Revisited: Not If, but When? J. Clin. Oncol., November 1, 2003; 21(21): 3894 - 3896. [Full Text] [PDF]

				A. Josting, S. Wiedenmann, J. Franklin, M. May, M. Sieber, J. Wolf, A. Engert, and V. Diehl Secondary Myeloid Leukemia and Myelodysplastic Syndromes in Patients Treated for Hodgkin's Disease: A Report From the German Hodgkin's Lymphoma Study Group J. Clin. Oncol., September 15, 2003; 21(18): 3440 - 3446. [Abstract] [Full Text] [PDF]

				J. O. Armitage, P. P. Carbone, J. M. Connors, A. Levine, J. M. Bennett, and S. Kroll Treatment-Related Myelodysplasia and Acute Leukemia in Non-Hodgkin's Lymphoma Patients J. Clin. Oncol., March 1, 2003; 21(5): 897 - 906. [Abstract] [Full Text] [PDF]

				C. Metayer, R. E. Curtis, J. Vose, K. A. Sobocinski, M. M. Horowitz, S. Bhatia, J. W. Fay, C. O. Freytes, S. C. Goldstein, R. H. Herzig, et al. Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control study Blood, March 1, 2003; 101(5): 2015 - 2023. [Abstract] [Full Text] [PDF]

				M. Hunault-Berger, N. Ifrah, and P. Solal-Celigny Intensive therapies in follicular non-Hodgkin lymphomas Blood, July 30, 2002; 100(4): 1141 - 1152. [Full Text] [PDF]

				C. Gisselbrecht, E. Lepage, T. Molina, B. Quesnel, G. Fillet, P. Lederlin, B. Coiffier, H. Tilly, J. Gabarre, F. Guilmin, et al. Shortened First-Line High-Dose Chemotherapy for Patients With Poor-Prognosis Aggressive Lymphoma J. Clin. Oncol., May 15, 2002; 20(10): 2472 - 2479. [Abstract] [Full Text] [PDF]

				C. Hosing, M. Munsell, S. Yazji, B. Andersson, D. Couriel, M. de Lima, M. Donato, J. Gajewski, S. Giralt, M. Korbling, et al. Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma Ann. Onc., March 1, 2002; 13(3): 450 - 459. [Abstract] [Full Text] [PDF]

				A. Rambaldi, M. Lazzari, C. Manzoni, E. Carlotti, L. Arcaini, M. Baccarani, T. Barbui, C. Bernasconi, G. Dastoli, G. Fuga, et al. Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma Blood, February 1, 2002; 99(3): 856 - 862. [Abstract] [Full Text] [PDF]

				M. Engelhardt, J. Finke, N. Rufer, T. H. Brummendorf, B. Chapuis, C. Helg, P. M. Lansdorp, and E. Roosnek Does telomere shortening count? Blood, August 1, 2001; 98(3): 888 - 890. [Full Text] [PDF]

				D. M. Lillington, I. N.M. Micallef, E. Carpenter, M. J. Neat, J. A.L. Amess, J. Matthews, N. J. Foot, B. D. Young, T. A. Lister, and A. Z.S. Rohatiner Detection of Chromosome Abnormalities Pre-High-Dose Treatment in Patients Developing Therapy-Related Myelodysplasia and Secondary Acute Myelogenous Leukemia After Treatment for Non-Hodgkin's Lymphoma J. Clin. Oncol., May 1, 2001; 19(9): 2472 - 2481. [Abstract] [Full Text] [PDF]

				S. J. Horning, R. S. Negrin, R. T. Hoppe, S. A. Rosenberg, N. J. Chao, G. D. Long, B. W. Brown, and K. G. Blume High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a phase II clinical trial Blood, January 15, 2001; 97(2): 404 - 409. [Abstract] [Full Text] [PDF]

				O. W. Press, J. F. Eary, T. Gooley, A. K. Gopal, S. Liu, J. G. Rajendran, D. G. Maloney, S. Petersdorf, S. A. Bush, L. D. Durack, et al. A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas Blood, November 1, 2000; 96(9): 2934 - 2942. [Abstract] [Full Text] [PDF]

				N. Mounier, C. Gisselbrecht, J. W. Friedberg, D. Neuberg, and A. S. Freedman Myelodysplasia After Autotransplantation J. Clin. Oncol., October 19, 2000; 18(19): 3446 - 3447. [Full Text] [PDF]

				C. Haioun, E. Lepage, C. Gisselbrecht, G. Salles, B. Coiffier, P. Brice, A. Bosly, P. Morel, C. Nouvel, H. Tilly, et al. Survival Benefit of High-Dose Therapy in Poor-Risk Aggressive Non-Hodgkin's Lymphoma: Final Analysis of the Prospective LNH87-2 Protocol--A Groupe d'Etude des Lymphomes de l'Adulte Study J. Clin. Oncol., August 16, 2000; 18(16): 3025 - 3030. [Abstract] [Full Text] [PDF]

				J. Pedersen-Bjergaard, M. K. Andersen, and D. H. Christiansen Therapy-related acute myeloid leukemia and myelodysplasia after high-dose chemotherapy and autologous stem cell transplantation Blood, June 1, 2000; 95(11): 3273 - 3279. [Abstract] [Full Text] [PDF]

				J. O. Armitage Myelodysplasia and Acute Leukemia After Autologous Bone Marrow Transplantation J. Clin. Oncol., March 1, 2000; 18(5): 945 - 945. [Full Text] [PDF]